Preclinical results to be presented at two international scientific
ZURICH, Switzerland, Feb. 25 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced that it has achieved high concentrations of its antibody fragments in all segments of the eye with topical delivery via eye drops. These data were confirmed in several independent preclinical in vivo tests. Anticipated therapeutic concentrations of ESBATech's antibody fragments were observed in the anterior chamber (front of the eye) and in the posterior segments (back of the eye) including vitreous humour, retina, and choroid. ESBATech's lead antibody fragment ESBA105 is a TNFa antagonist that is scheduled to enter clinical development later in 2008.
ESBATech also announced today that it will present its preclinical eye penetration data at two upcoming scientific conferences. Dominik Escher, Ph.D., ESBATech's Chief Executive Officer will present at Antibody Engineering Asia in Singapore on February 26, 2008. David Urech, Ph.D., Head of Research & Development at ESBATech will present at the ISOPT 2008 (International Symposium on Ocular Pharmacology and Therapeutics) in Budapest on February 29, 2008.
Dr. Urech commented, "ESBATech's proprietary, repeatable screening
platform was employed and generated multiple promising antibody fragment
product candidates against several targets for topical ophthalmic use.
Antibody fragments have a number of advantages over whole antibodies,
resulting from their smaller molecular size. The primary advantage of human
antibody fragment is their ability to penetrate tissues much better than
whole antibodies. We believe that with our highly stable and monomeric
single-chain antibody fragments, we now meet the protein requirem
|SOURCE ESBATech AG|
Copyright©2008 PR Newswire.
All rights reserved